<DOC>
	<DOC>NCT00285428</DOC>
	<brief_summary>This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.</brief_summary>
	<brief_title>Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>CD20+ Bcell nonHodgkin's lymphoma (NHL) with measurable disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>treatment</keyword>
	<keyword>NHL</keyword>
	<keyword>CD20+ B-cell NHL</keyword>
	<keyword>Lymphoma</keyword>
</DOC>